CN101506161B - 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 - Google Patents
具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 Download PDFInfo
- Publication number
- CN101506161B CN101506161B CN2006800556054A CN200680055605A CN101506161B CN 101506161 B CN101506161 B CN 101506161B CN 2006800556054 A CN2006800556054 A CN 2006800556054A CN 200680055605 A CN200680055605 A CN 200680055605A CN 101506161 B CN101506161 B CN 101506161B
- Authority
- CN
- China
- Prior art keywords
- ethyl ester
- methyl
- ester acetate
- lignocaine ethyl
- carbon atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc(cc1)cc2c1c1cc(*)ccc1[n]2 Chemical compound Cc(cc1)cc2c1c1cc(*)ccc1[n]2 0.000 description 4
- HXKOULWOCFMQFL-UHFFFAOYSA-N Cc(cc1)cc(C2)c1Oc1c2cccn1 Chemical compound Cc(cc1)cc(C2)c1Oc1c2cccn1 HXKOULWOCFMQFL-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
组别 | 剂量(mg/kg) | 扭体次数 | 抑制率(%) |
A | 0 | 35.0 | - |
B | 100 | 17.1 | 51 |
C | 100 | 15.7 | 55 |
D | 100 | 13.8 | 61 |
E | 100 | 15.6 | 55 |
F | 100 | 14.2 | 59 |
G | 100 | 16.1 | 54 |
H | 100 | 17.1 | 51 |
I | 100 | 15.6 | 55 |
J | 100 | 13.2 | 62 |
K | 100 | 14.0 | 60 |
L | 100 | 14.2 | 59 |
M | 100 | 13.8 | 61 |
N | 100 | 15.7 | 55 |
O | 100 | 13.2 | 62 |
P | 100 | 15.2 | 57 |
Q | 100 | 15.7 | 55 |
R | 100 | 14.2 | 59 |
S | 100 | 15.6 | 55 |
T | 100 | 16.1 | 54 |
U | 100 | 15.2 | 57 |
化合物 | t=0min. | t=90min. | t=180min. | t=270min. |
A(对照组) | 37.34±0.05 | 37.36±0.07 | 37.37±0.05 | 37.44±0.08 |
E(100mg/kg) | 37.33±0.07 | 36.80±0.06 | 36.72±0.05 | 36.50±0.08 |
F(100mg/kg) | 37.28±0.06 | 36.65±0.06 | 36.58±0.08 | 36.45±0.07 |
B(100mg/kg) | 37.35±0.06 | 36.71±0.05 | 36.60±0.08 | 36.59±0.07 |
M(100mg/kg) | 37.29±0.07 | 36.82±0.06 | 36.70±0.05 | 36.67±0.08 |
C(100mg/kg) | 37.28±0.06 | 36.68±0.05 | 36.62±0.08 | 36.58±0.07 |
D(100mg/kg) | 37.27±0.06 | 36.76±0.05 | 36.65±0.08 | 36.49±0.07 |
E(100mg/kg) | 37.25±0.07 | 36.82±0.06 | 36.70±0.05 | 36.50±0.08 |
F(100mg/kg) | 37.23±0.06 | 36.69±0.06 | 36.52±0.08 | 36.40±0.07 |
J(100mg/kg) | 37.26±0.06 | 36.65±0.06 | 36.58±0.08 | 36.36±0.07 |
G(100mg/kg) | 37.27±0.06 | 36.68±0.05 | 36.62±0.08 | 36.58±0.07 |
H(100mg/kg) | 37.25±0.06 | 36.71±0.05 | 36.65±0.08 | 36.64±0.07 |
I(100mg/kg) | 37.26±0.07 | 36.80±0.06 | 36.70±0.05 | 36.57±0.08 |
H(100mg/kg) | 37.25±0.06 | 36.71±0.05 | 36.65±0.08 | 36.64±0.07 |
J(100mg/kg) | 37.28±0.06 | 36.65±0.06 | 36.58±0.08 | 36.56±0.07 |
K(100mg/kg) | 37.25±0.06 | 36.75±0.05 | 36.62±0.08 | 36.58±0.07 |
M(100mg/kg) | 37.24±0.07 | 36.82±0.06 | 36.70±0.05 | 36.67±0.08 |
L(100mg/kg) | 37.23±0.06 | 36.81±0.05 | 36.65±0.08 | 36.61±0.07 |
M(100mg/kg) | 37.29±0.07 | 36.82±0.06 | 36.60±0.05 | 36.67±0.08 |
J(100mg/kg) | 37.22±0.06 | 36.65±0.06 | 36.58±0.08 | 36.51±0.07 |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310470404.2A CN103705496B (zh) | 2006-08-15 | 2006-08-15 | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2006/052815 WO2008020270A1 (en) | 2006-08-15 | 2006-08-15 | Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310470404.2A Division CN103705496B (zh) | 2006-08-15 | 2006-08-15 | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101506161A CN101506161A (zh) | 2009-08-12 |
CN101506161B true CN101506161B (zh) | 2013-11-13 |
Family
ID=39081992
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800556054A Active CN101506161B (zh) | 2006-08-15 | 2006-08-15 | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2054384A4 (zh) |
JP (1) | JP5424880B2 (zh) |
CN (1) | CN101506161B (zh) |
AU (1) | AU2006347391B2 (zh) |
CA (1) | CA2660814C (zh) |
HK (1) | HK1137425A1 (zh) |
WO (1) | WO2008020270A1 (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
WO2008010025A1 (en) * | 2006-07-18 | 2008-01-24 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate |
US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
CA2665081C (en) | 2006-10-02 | 2015-12-01 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
CA2668500C (en) | 2006-11-08 | 2018-07-31 | Chongxi Yu | Transdermal delivery systems of peptides and related compounds |
EP2656879B1 (en) | 2006-12-10 | 2017-06-28 | Chongxi Yu | Transdermal delivery systems of beta-lactam antibiotics |
WO2008087493A1 (en) | 2007-01-15 | 2008-07-24 | Chongxi Yu | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
CA2675845C (en) | 2007-01-31 | 2019-03-05 | Chongxi Yu | Positively charged water-soluble prodrugs of 1h-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates |
DK2170826T3 (da) * | 2007-06-04 | 2022-07-11 | Techfields Inc | Nsaia-pro-lægemidler med meget høje hud- og membranpenetrationshastigheder og deres nye medicinske anvendelser |
CN102307857A (zh) * | 2008-12-04 | 2012-01-04 | 于崇曦 | 高穿透性组合物及其它们的应用 |
KR20180110187A (ko) | 2009-05-08 | 2018-10-08 | 테크필즈 바이오켐 코., 엘티디. | 펩티드 및 펩티드관련 화합물의 고침투성 전구약물 조성물 |
US9969751B2 (en) | 2009-06-10 | 2018-05-15 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds |
IN2014KN02583A (zh) | 2012-01-18 | 2015-05-08 | Techfields Pharma Co Ltd | |
CA3212170A1 (en) | 2013-03-15 | 2014-09-18 | Techfields Pharma Co., Ltd. | Novel high penetration drugs and their compositions thereof for treatment of parkinson diseases |
JP5940036B2 (ja) * | 2013-10-08 | 2016-06-29 | テックフィールズ バイオケム カンパニー リミテッド | 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ |
WO2016073738A2 (en) | 2014-11-05 | 2016-05-12 | Flexus Biosciences, Inc. | Immunoregulatory agents |
US9862698B2 (en) | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
JP6290947B2 (ja) * | 2016-02-05 | 2018-03-07 | テックフィールズ バイオケム カンパニー リミテッド | 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ |
WO2019210223A1 (en) | 2018-04-26 | 2019-10-31 | Adt Pharmaceuticals, Llc | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
US20220274911A1 (en) * | 2020-09-09 | 2022-09-01 | Nanjing Heron Pharmaceutical Science And Technology Co., Ltd. | Arylpropionic acid derivative, pharmaceutical composition and preparation method and application thereof |
CN117916219A (zh) * | 2021-07-06 | 2024-04-19 | 石家庄迪斯凯威医药科技有限公司 | 一类抗膀胱癌的季胺盐化合物及其应用 |
WO2023046078A1 (zh) * | 2021-09-24 | 2023-03-30 | 石家庄迪斯凯威医药科技有限公司 | 一种新型普拉洛芬衍生物及其药物组合物和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0289262A2 (en) * | 1987-04-27 | 1988-11-02 | Syntex Pharmaceuticals International Limited | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1593024A (zh) * | 1968-09-18 | 1970-05-25 | ||
CA1012159A (en) * | 1972-06-27 | 1977-06-14 | Michael Marx | Dialkylaminoalkyl esters of 2-(6-methoxy-2-naphthyl) propionic acid and the pharmaceutically acceptable salts thereof |
US3896145A (en) * | 1972-07-24 | 1975-07-22 | Hoffmann La Roche | Carbazoles |
ZA738203B (en) * | 1972-10-24 | 1975-05-28 | Janssen Pharmaceutica Nv | Aroyl-substituted phenylacetic acid derivatives |
JPS5826744B2 (ja) * | 1975-12-24 | 1983-06-04 | ヒサミツセイヤク カブシキガイシヤ | シンキナプロピオンサン エステルユウドウタイノセイゾウホウ |
IT1090782B (it) * | 1977-11-30 | 1985-06-26 | Menarini Sas | 2 4 bifenilil 2 dietilamino alchil propionamide suoi sali e procedimenti di fabbricazione relativi |
JPS58126846A (ja) * | 1982-01-22 | 1983-07-28 | Kaken Pharmaceut Co Ltd | プロピオン酸アミノアルキルエステル誘導体、その製法およびそれを有効成分とする消炎、鎮痛剤 |
IT1317826B1 (it) * | 2000-02-11 | 2003-07-15 | Dompe Spa | Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8. |
ITMI20010395A1 (it) * | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
ITMI20012025A1 (it) * | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
-
2006
- 2006-08-15 WO PCT/IB2006/052815 patent/WO2008020270A1/en active Application Filing
- 2006-08-15 CN CN2006800556054A patent/CN101506161B/zh active Active
- 2006-08-15 CA CA2660814A patent/CA2660814C/en active Active
- 2006-08-15 AU AU2006347391A patent/AU2006347391B2/en not_active Ceased
- 2006-08-15 EP EP06795662A patent/EP2054384A4/en active Pending
- 2006-08-15 JP JP2009524242A patent/JP5424880B2/ja not_active Expired - Fee Related
-
2010
- 2010-01-28 HK HK10100928.5A patent/HK1137425A1/zh unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0289262A2 (en) * | 1987-04-27 | 1988-11-02 | Syntex Pharmaceuticals International Limited | Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs |
Non-Patent Citations (1)
Title |
---|
宋妮等.一种布洛芬季铵盐衍生物的合成.《青岛海洋大学学报》.2002,第32卷(第6期),911-913. * |
Also Published As
Publication number | Publication date |
---|---|
JP5424880B2 (ja) | 2014-02-26 |
HK1137425A1 (zh) | 2010-07-30 |
AU2006347391B2 (en) | 2013-03-07 |
AU2006347391A1 (en) | 2008-02-21 |
EP2054384A1 (en) | 2009-05-06 |
CA2660814A1 (en) | 2008-02-21 |
EP2054384A4 (en) | 2010-11-03 |
CA2660814C (en) | 2017-07-18 |
WO2008020270A1 (en) | 2008-02-21 |
CN101506161A (zh) | 2009-08-12 |
JP2010500989A (ja) | 2010-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101506161B (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 | |
CN101506168B (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基邻氨基苯甲酸的前药 | |
CN101489985B (zh) | 具有快速皮肤穿透率的带正电荷的水溶性布洛芬前药 | |
EP2049482B1 (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate | |
EP2046727A1 (en) | Positively charged water-soluble prodrugs of diclofenac with very fast skin penetration rate | |
CN101500984A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性酮洛芬及相关化合物的前药 | |
AU2013206218B2 (en) | Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate | |
JP5940036B2 (ja) | 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ | |
CN103705496B (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基和杂芳基丙酸类前药 | |
JP5629745B2 (ja) | 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ | |
CN103772259B (zh) | 具有快速皮肤穿透速度的带正电荷的芳基和杂芳基乙酸类前药 | |
JP6290947B2 (ja) | 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ | |
CN103772258B (zh) | 具有快速皮肤穿透速度的带正电荷的芳基和杂芳基乙酸类前药 | |
CN104706630B (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的芳基邻氨基苯甲酸的前药 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1137425 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1137425 Country of ref document: HK |
|
CP01 | Change in the name or title of a patent holder |
Address after: Illinois, America Patentee after: Yu Chongxi Patentee after: Taifeier biomedical (Suzhou) Co.,Ltd. Address before: Illinois, America Patentee before: Yu Chongxi Patentee before: Shanghai Taifeier Biochemical Technology Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220525 Address after: 215129 Room 401, building 9, No. 168, Majian Road, high tech Zone, Suzhou, Jiangsu Province Patentee after: Taifeier biomedical (Suzhou) Co.,Ltd. Address before: Illinois, America Patentee before: Yu Chongxi Patentee before: Taifeier biomedical (Suzhou) Co.,Ltd. |
|
TR01 | Transfer of patent right |